Literature DB >> 29985717

Defective Treg response in acute kidney injury was caused by a reduction in TIM-3+ Treg cells.

Qin Dong1, Chen Cai2, Feng Gao1, Pei Chen1, Weixin Gong1, Meihua Shen3.   

Abstract

BACKGROUND: Despite years of research, the treatment of acute kidney injury (AKI) remains a significant challenge. Animal studies presented causal links between elevated regulatory T cell (Treg) response and better prognosis in AKI. Previous studies in mice and humans showed that TIM-3+ Treg cells were more potent than TIM-3- Treg cells. In this study, we investigated the role of TIM-3 in Treg in AKI patients.
METHODS: Peripheral blood from AKI patients and healthy controls were gathered, and TIM-3+ Treg subset was examined.
RESULTS: Compared to healthy controls, the AKI patients presented a significant upregulation in the frequency of circulating CD4+CD25+ T cells; however, the majority of this increase was from the CD4+CD25+TIM-3- subset, and the frequency of CD4+CD25+TIM-3+ T cells was downregulated in AKI patients. In both healthy controls and AKI patients, the CD4+CD25+TIM-3+ T cells expressed higher levels of Foxp3, and were more potent at expressing LFA-1, LAG-3, CTLA-4, IL-10 and TGF-β. In addition, the CD4+CD25+TIM-3+ T cells from both healthy controls and AKI patients presented higher capacity to suppress CD4+CD25- T cell proliferation than the CD4+CD25+TIM-3- T cells. Interestingly, the total CD4+CD25+ T cells from AKI patients presented significantly lower inhibitory capacity than those from healthy controls, indicating that the low frequency of CD4+CD25+TIM-3+ T cells was restricting the efficacy of the Treg responses in AKI patients.
CONCLUSIONS: We demonstrated that TIM-3 downregulation impaired the function of Treg cells in AKI. The therapeutic potential of CD4+CD25+TIM-3+ T cells in AKI should be investigated in future studies.

Entities:  

Keywords:  Acute kidney injury; Tim-3; Treg

Mesh:

Substances:

Year:  2018        PMID: 29985717     DOI: 10.1080/08820139.2018.1493497

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Clinical value of the sTim‑3 level in chronic kidney disease.

Authors:  Lingli Chen; Yuan Qin; Bo Lin; Xiaomei Yu; Shaoxiong Zheng; Xiumei Zhou; Xiaobin Liu; Yigang Wang; Biao Huang; Juan Jin; Liang Wang
Journal:  Exp Ther Med       Date:  2022-07-29       Impact factor: 2.751

2.  A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment.

Authors:  Elena Pérez-Antón; Adriana Egui; M Carmen Thomas; Bartolomé Carrilero; Marina Simón; Miguel Ángel López-Ruz; Manuel Segovia; Manuel Carlos López
Journal:  PLoS Negl Trop Dis       Date:  2021-02-04

3.  An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation.

Authors:  Can Lu; Huihui Chen; Chang Wang; Fei Yang; Jun Li; Hong Liu; Guochun Chen
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

4.  The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.

Authors:  Jie Zhu; Peiqi Fang; Chong Wang; Meixiu Gu; Baishen Pan; Wei Guo; Xinrong Yang; Beili Wang
Journal:  Cancer Med       Date:  2021-10-04       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.